Literature DB >> 2557619

v-src induces clonal sarcomas and rapid metastasis following transduction with a replication-defective retrovirus.

A W Stoker1, M H Sieweke.   

Abstract

v-src is an effective carcinogen when expressed from Rous sarcoma virus (RSV) in vivo. Whereas RSV tumors require sustained oncogene expression, their growth is largely a balance between viral recruitment of tissues and host immune destruction of infected cells. We have therefore examined the tumorigenic potential of v-src in the absence of viral recruitment and viral antigen expression. v-src was introduced with high efficiency into chicken wing web tissues using replication-defective (rd) retroviral vectors. Clonal sarcomas were induced rapidly, and, furthermore, v-src potentiated metastatic progression in approximately 0.1%-1% of tumor clones with unexpectedly short latency. rd vectors proved effective not only in transducing v-src into tissues but also as insertional markers of tumor clonality. The rd vector present in most primary and metastatic tumors was a highly truncated form of RSV derived by viral transmission of spliced v-src mRNA; this vector should thus avoid viral recruitment and host anti-viral immune reaction through its complete lack of viral structural genes. Under such conditions v-src maintains strong carcinogenicity in vivo when restricted to clonal tumor growth and can confer rapid metastatic potential on a discrete subset of tumor clones.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2557619      PMCID: PMC298657          DOI: 10.1073/pnas.86.24.10123

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  14 in total

1.  Quantitative studies on Rous sarcoma virus. IV. An investigation of the nature of "noninfective" tumors induced by low doses of virus.

Authors:  A M PRINCE
Journal:  J Natl Cancer Inst       Date:  1959-12       Impact factor: 13.506

2.  Development of avian sarcoma and leukosis virus-based vector-packaging cell lines.

Authors:  A W Stoker; M J Bissell
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

3.  Quantitative immunocytochemical assay for infectious avian retroviruses.

Authors:  A W Stoker; M J Bissell
Journal:  J Gen Virol       Date:  1987-09       Impact factor: 3.891

4.  In vitro RNA synthesis with SP6 RNA polymerase.

Authors:  P A Krieg; D A Melton
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

5.  The LTR, v-src, LTR provirus generated in the mammalian genome by src mRNA reverse transcription and integration.

Authors:  J Bodor; J Svoboda
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

6.  Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction.

Authors:  K B Mullis; F A Faloona
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

7.  Expression of a subgenomic retroviral messenger RNA.

Authors:  D W Stacey
Journal:  Cell       Date:  1980-10       Impact factor: 41.582

8.  pp60v-src tyrosine kinase is expressed and active in sarcoma-free avian embryos microinjected with Rous sarcoma virus.

Authors:  A R Howlett; V C Carter; G S Martin; M J Bissell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

9.  Cellular and humoral anti-tumor immune responsiveness in chickens bearing tumors induced by avian sarcoma virus.

Authors:  M A Wainberg; M Yu; E Schwartz-Luft; E Israël
Journal:  Int J Cancer       Date:  1977-05-15       Impact factor: 7.396

10.  Tumor induction by direct injection of cloned v-src DNA into chickens.

Authors:  Y K Fung; L B Crittenden; A M Fadly; H J Kung
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

View more
  10 in total

1.  Tumor induction by the LTR, v-src, LTR DNA in four B (MHC) congenic lines of chickens.

Authors:  J Svoboda; J Plachý; J Hejnar; I Karakoz; R V Guntaka; J Geryk
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

2.  Similar expression profiles of a core of genes and proteins in cells that have acquired a metastatic phenotype, genetically or by in vivo evolution.

Authors:  Laila Illán Rubio; Bertrand Tavitian; Elina Zueva
Journal:  Clin Exp Metastasis       Date:  2009-11-11       Impact factor: 5.150

3.  Chicken sarcoma to human cancers: a lesson in molecular therapeutics.

Authors:  Om Prakash; Stephen F Bardot; John T Cole
Journal:  Ochsner J       Date:  2007

4.  Distinct and opposite roles for SH2 and SH3 domains of v-src in embryo survival and hemangiosarcoma formation.

Authors:  John C Morgan; John E Majors; Deni S Galileo
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

5.  FRNK blocks v-Src-stimulated invasion and experimental metastases without effects on cell motility or growth.

Authors:  Christof R Hauck; Datsun A Hsia; Xose S Puente; David A Cheresh; David D Schlaepfer
Journal:  EMBO J       Date:  2002-12-02       Impact factor: 11.598

6.  The embryonic environment strongly attenuates v-src oncogenesis in mesenchymal and epithelial tissues, but not in endothelia.

Authors:  A W Stoker; C Hatier; M J Bissell
Journal:  J Cell Biol       Date:  1990-07       Impact factor: 10.539

7.  src-specific immunity in inbred chickens bearing v-src DNA- and RSV-induced tumors.

Authors:  J Plachý; K Hála; J Hejnar; J Geryk; J Svoboda
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

8.  The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos.

Authors:  I R Ghattas; J R Sanes; J E Majors
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

9.  Tumor immunity generated in the course of regression of v-src-induced sarcomas.

Authors:  T W Wisner; J M England; D Y Pan; A W Stoker; M S Halpern
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

10.  Loss of transformed phenotype upon senescence of Rous sarcoma virus-infected chicken neuroretinal cells.

Authors:  G M Seigel; M F Notter
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.